Emergent BioSolutions (EBS) CEO gets 252,194 options as 37,055 shares withheld for taxes

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Emergent BioSolutions Inc. reported that President and CEO Joseph C. Papa received an award of employee stock options covering 252,194 shares on March 3, 2026, at an exercise price of $0.00 per share. These options vest in three equal installments beginning the day prior to each anniversary of the grant date.

On March 5, 2026, 37,055 shares of common stock were withheld and disposed of to cover taxes tied to the vesting and settlement of performance stock units at a price of $8.44 per share, leaving Papa with 305,445 common shares directly owned.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider PAPA JOSEPH C

Role President and CEO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	37,055	$8.44	$313K
Grant/Award	Employee Stock Option (Right to buy)	252,194	$0.00	--

Holdings After Transaction: Common Stock — 305,445 shares (Direct); Employee Stock Option (Right to buy) — 1,784,694 shares (Direct)

Footnotes (1)

Represents shares of common stock withheld to pay taxes associated with vesting and settlement of performance stock units. Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

Form 4 Insider Transactions: What Each Field Means →

03/05/2026 - 09:40 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PAPA JOSEPH C

(Last)

(First)

(Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG

20879

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/05/2026		F		37,055⁽¹⁾	D	$8.44	305,445	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (Right to buy)	$8.99	03/03/2026		A		252,194		⁽²⁾	03/02/2033	Common Stock	252,194	$0	1,784,694	D

Explanation of Responses:

1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of performance stock units.

2. Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Emergent BioSolutions (EBS) report for Joseph C. Papa?

Emergent BioSolutions reported that President and CEO Joseph C. Papa received an employee stock option grant for 252,194 shares and had 37,055 common shares withheld and disposed of to satisfy tax obligations linked to vesting performance stock units.

How many Emergent BioSolutions (EBS) stock options were granted to CEO Joseph C. Papa?

Joseph C. Papa was granted employee stock options covering 252,194 shares of Emergent BioSolutions common stock. The options were awarded at an exercise price of $0.00 per share and vest in three equal installments starting the day before each anniversary of the grant date.

Why were 37,055 Emergent BioSolutions (EBS) shares disposed of for Joseph C. Papa?

The 37,055 Emergent BioSolutions common shares were withheld and disposed of to pay taxes arising from the vesting and settlement of performance stock units for Joseph C. Papa, rather than being an open-market sale initiated for investment purposes.

What is Joseph C. Papa’s direct common shareholding in Emergent BioSolutions after these transactions?

Following the tax-withholding disposition of 37,055 shares, Joseph C. Papa directly owns 305,445 shares of Emergent BioSolutions common stock. This figure reflects his direct holdings after the shares were withheld to cover tax obligations related to performance stock units.

How do the new Emergent BioSolutions (EBS) stock options for Joseph C. Papa vest?

The newly granted Emergent BioSolutions employee stock options for Joseph C. Papa vest in three equal installments. Each installment vests on the day prior to the anniversary date of the grant, spreading vesting over three annual milestones tied to the original grant date.